NicholasAButowskiMD

PubMed

• 129 citations
  Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
  Louis B. Nabors, Jana Portnow, Manmeet Ahluwalia, Joachim Baehring, Henry Brem
  Journal of the National Comprehensive Cancer Network. 2020-11-02
• 15 citations
  The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma
  Biswarathan Ramani, Rohit Gupta, Jasper Wu, Jairo Barreto, Andrew W. Bollen
  Acta Neuropathologica. 2020-09-06
• 15 citations
  Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
  Yalan Zhang, Calixto-Hope G Lucas, Jacob S Young, Ramin A Morshed, Lucie McCoy
  Neuro-Oncology. 2022-10-03

Journal Articles

• The Genetic Landscape of Gliomas Arising After Therapeutic Radiation  
  Iwei Yeh, Corey Raffel, Mitchel Berger, Joanna J Phillips, James P Grenert, Boris C Bastian, David A Solomon, Nicholas Butowski, Sabine Mueller, Cassie Kline, Manish A..., Acta Neuropathologica
• A Single-institution Phase II Trial of Radiation, Temozolomide, Erlotinib, and Bevacizumab for Initial Treatment of Glioblastoma  
  Clarke, J.L., Molinaro, A.M., Butowski, N.A., Chang, S.M., Phillips, J.J., Perry, A., Costello, J.F., DeSilva, A.A., Rabbitt, J.E., Prados, M.D., Neuro Oncol., 1/1/2014
• General and Neurological Complications of Targeted Therapy  
  Butowski NA, Chang SM, Handbook of Clinical Neurology, 1/1/2012
• Endpoints for Clinical Trials and Revised Assessment in Neurooncology  
  Butowski N, Chang SM, Current Opinion in Neurology, 1/1/2012
• Individual Patient-specific Immunity against High-grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein  
  Crane CA, Han SJ, Ahn BJ, Oehlke J, Kivett V, Butowski N, et al., Clinical Cancer Research, 1/1/2012
• Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients with Advanced Solid Tumors  
  Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al., Journal of Clinical Oncology, 1/1/2012
• Medical Management of Brain Metastases  
  Butowski N, Neurosurgery Clinics of North America, 1/1/2011
• Phase II and Pharmacogenomics Study of Enzastaurin plus Temozolomide during and following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme an...  
  Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, et al., Neuro-oncology., 1/1/2011
• Identifying the Needs of Brain Tumor Patients and Their Caregivers  
  Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, et al., Journal of Neuro-oncology, 1/1/2011
• Conditional Probability of Survival in Patients with Newly Diagnosed Glioblastoma  
  Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M, Journal of Clinical Oncology, 1/1/2011
• Anti-angiogenic Therapy in Glioma  
  Butowski N, Clinical & Translational Oncology, 1/1/2011
• Phase II and Pharmacogenomics Study of Enzastaurin plus Temozolomide during and following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme an...  
  Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, et al., Neuro-oncology, 1/1/2011
• Anti-angiogenic Therapy in Glioma  
  Butowski N, Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 1/1/2011
• Recent Advances in Therapy for Glioblastoma  
  Clarke J, Butowski N, Chang S, Archives of Neurology, 1/1/2010
• Immunostimulants for Malignant Gliomas  
  Butowski N, Neurosurgery Clinics of North America, 1/1/2010
• Enzastaurin plus Temozolomide with Radiation Therapy in Glioblastoma Multiforme: A Phase I Study  
  Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, et al., Neuro-oncology, 1/1/2010
• Phase I Pharmakokinetic and Pharmacodynamic Study of Enzastaurin plus Temozolomide During and Following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma...  
  Nicholas Butowski M.D.,Susan M. Chang M.D, Kathleen R. Lamborn Ph.D., Mei Yin Polley PhD. Michael D. Prados M.D., Neuro Oncol, 1/1/2010
• Phase II Study of Erlotinib plus Temozolomide during and after Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma  
  Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al., Journal of Neuro-oncology, 1/1/2009
• Diagnosis and Treatment of Recurrent High-grade Astrocytoma  
  Butowski NA, Sneed PK, Chang SM, Journal of Clinical Oncology, 1/1/2006
• Glial Tumors: The Current State of Scientific Knowledge  
  Butowski NA, Chang SM, Clinical Neurosurgery, 1/1/2006
• Join now to see all

Books/Book Chapters

• Glioblastoma: Epidemiology, Risk Factors, Diagnosis, and Treatment Options 
  Butowski, NNova Publishers2011
• The Neurosurgeon's Handbook 
  Chapter: Neuro-Oncology 
  Butowski N, Liu R, Berger MEditors: George Samandouras.Oxford University Press2010
• Imaging of the Spine 
  Chapter: Managing the Tumor Patient 
  Butowski NEditors: Naidich T.Elsevier Press2010
• Cancer Neurology in Clinical Practice 
  Chapter: Metastases to the Peripheral Nervous System 
  Butowski NEditors: Kesari S.Humana Press2008
• Current Clinical Oncology 
  Chapter: Adult High Grade Glioma 
  Butowski N, Chang S2008
• Cancer Therapy 
  Chapter: Brain Cancer 
  Butowski N, Prados M, McDermott M, Chang SAndrews McNeel Publishing2008
• Neuro-Oncology: The Essentials 
  Chapter: Complications of Medical Therapy 
  Butowski N, Chang SEditors: Berger M.Thieme Inc2008
• Congress of Neurological Surgeons Handbook 
  Chapter: Current State of Brain Tumors 
  Butowski N, Chang S.2007
• Handbook of Brain Tumor Chemotherapy 
  Chapter: Clinical Trial Design and Implementation 
  Butowski N, Chang SEditors: Newton H.Elsevier Inc2006
• Join now to see all

Abstracts/Posters

• Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma Multiforme (GBM).
  Kent C. Shih, Manish R. Patel, Nicholas A. Butowski, Jeffrey A. Bacha, Dennis Brown, William J. Garner, Anne Steino, Richard Stephen Schwartz, Sarath Kanekal, Lorena L..., ASCO Annual Meeting, 1/1/2014
• A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma
  N. Butowski, H. Colman, J. DeGroot A. Yung, A. Omuro, L. Nayak, T. Cloughsey, A. Marimuthu, A. Perry , J. Phillips , J. Joyce , B. L. West , M. Prados , K. Nolop, H..., ASCO Annual Meeting, 1/1/2014
• OMX-4.80 An Engineered Oxygen Carryig Protein Oxygenetes Hypoxic Tumors and Increase the Efficacy of Radiotherapy in Orthotopic Models of Glioblastoma
  Laura Serwer, Raquel Santos, Saharh Ng, Nicholas Butowski, Ana Krloitica, Tomoko OZawa, Stephen Cary, David James, World Federation of Neuro-Oncology Quadrennial Meeting, San Francisco, CA, 1/1/2014
• Imaging Parameters and Molecular Correlates as Predictive Markers of Treatment Response to mTOR Inhibition in Adults with Recurrent Low-grade Gliomas
  Daphne Haas-Kogan, Joanna J. Phillips, Annette Molinaro, Michael Wahl, Sabine Mueller, William A. Weiss, Janine M. Lupo, Mitchel S. Berger, Michael Prados, Nicholas Bu..., AACR Annual Meeting, University of California, San Francisco, San Francisco, CA, 1/1/2013
• Development of Atypical and AnaplasticMeningiomaCell Resources: Results From Three Years Experience at UCSF
  C. David James, Nicholas Butowski, Rintaro Hashizume, Yu-Jen Lu, AriePerry, Andrew Parsa, and Michael McDermott, AANS Joint Section on Tumors Meningioma Session, 1/1/2013
• OMX-4.80 An Engineered Oxygen Carryig Protein Oxygenetes Hypoxic Tumors and Increase the Efficacy of Radiotherapy in Orthotopic Models of Glioblastoma
  Laura Serwer, Yasuyuki Yoshida, Natacha Le Moan, Raquel Santos, Sarah Ng, Nicholas Butowski, Ana Krtolica, Tomoko Ozawa, Stephen P.L. Cary, and C. David James, World Federation Meeting of Neuro-Oncology, San Francisco CA, 1/1/2013
• Dermatologic Event Characteristics and Management with the NovoTTF-100A System, a Novel Anti-Mitotic Device for the Treatment of Recurrent Glioblastoma (rGBM).
  M.E. Lacouture 1, M.E. Davis 1, G. Elzinga 2, N. Butowski 3, D. Tran 4, J.L. Villano 5, and E.T. Wong, World Federation Meeting of Neuro-Oncology, San Francisco CA, 1/1/2013
• Preclinical Evaluation of NT113, a Novel ERBB Inhibitor Optimiazed for CNS Distribution
  Y Yushida, T Ozawa, N Butowski, W Shen, D Brown, H Pedersen, C David James, World Federation Meeting of Neuro-oncology, San Francisco CA, 1/1/2013
• A Single-institution Phase II Trial of Radiation (RT), Temozolomide(TMZ), Erlotiniband Bevacizumabfor Initial Treatment of Glioblastoma(GBM)
  JL Clarke, MD, MPH, AM Molinaro, PhD, NA Butowski, MD, SM Chang, MD, JJ Phillips, MD, PhD, JF Costello, PhD, BM Costa, PhD, JE Rabbitt, RN, BSN, VA Kivett, BS, AA DeSi..., ASCO, 1/1/2012
• Integrating physiological MRI with Assessment of Neurocognitve Function
  Janine M. Lupo, Caroline A. Racine, Angela Jakary, Annette Molinaro, Anna Parks, Susan M. Chang, Sarah J. Nelson, Mitchel S. Berger, and Nicholas Butowski, SNO Annual Meeting, 1/1/2012
• A Comprehensive Evaluation of Cognition in Newly Diagnosed High-grade Glioma
  Caroline A. Racine, Janine M. Lupo, Annette Molinaro, Anna Parks, Susan/> M. Chang, Mitchel S. Berger, and Nicholas Butowski, SNO Annual Meeting, Washington DC, 1/1/2012
• Comparison of Systemic versus Direct Intratumoral Administration of Nanoliposomal Irinotecan, with and without Fractionated Radiotherapy, for Efficacy in Treating Orth...
  Pin-Yuan Chen, Tomoko Ozawa, Daryl Drummond, Raquel Santos, ,Jacqueline D. Torre, Christina Ng, Edgar L. Lepe, Nicholas Butowski, Michael Prados, Krystof Bankiewicz, a..., SNO Annual Meeting, Washington DC, 1/1/2012
• Diffusion Imaging Parameters Vary with Treatment Regimen for Patients with Newly Diagnosed Glioblastoma Multiforme
  Laleh Jalilian, Emma Essock-Burns, Soonmee Cha, Susan Chang, Michael Prados, Nicholas Butowski, Sarah Nelson, SNO Annual Meeting, UCSF, San Francisco, CA, 2011; Anaheim,CA, 2011, 1/1/2011
• Autologous Heat Shock Protein Vaccine (HSPPC-96) For Patients with Recurrent Glioblastoma (GBM): Results of a Phase II Multicenter Clinical Trial with Immunological As...
  A. Parsa, C. Crane, S. Han, V. Kivett, A. Fedoroff, N. A. Butowski, S. M. Chang, J. L. Clarke, M. S. Berger, M. McDermott, M. Aghi, C. Yanes, M. Prados, A. E. Sloan, J..., ASCO Annual Meeting, Multiple locations, 1/1/2011
• Phase 2 Study of Enzastaurin plus Temozolomide during and following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) Or Gliosarcoma
  N. Butowski, K. Lamborn, S. Chang, D. Thornton, M. Page, Kivett, S. Nicol, M. Prados., American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2010
• The Conditional Probability of Survival in Newly-diagnosed Glioblastoma Patients
  Mei-Yin C. Polley, Kathleen R. Lamborn, Susan M. Chang, Nicholas Butowski, Jennifer L. Clarke, and Michael Prados, Society of Neuro-Oncology Annual Meeting, Montreal, Canada, 1/1/2010
• Assessment of Diffusion Parameters in Scans prior to Progression in GBM Patients following Antiangiogenic Therapy
  L. Jalilian, E. Essock-Burns, S. M. Chang, S. Cha, N. Butowski, and S. J. Nelson, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2010
• Anatomic and Diffusion-weighted MR Imaging Characteristics of Recurrent Glioblastoma Multiforme Treated with Bevacizumab
  Kerlan, K., Chang, J.S., Barajas, R., Butowski, N., Cha, S., American Society of Neuroradiology Annual Meeting, Boston, MA, 1/1/2010
• Comparison of DSC-derived Perfusion Parameters in Response to Conventional Therapy or Adjuvant Anti-angiogenic Therapy in Patients Newly-Diagnosed with GBM
  E. Essock-Burns, J. M. Lupo , S. Cha, N. Butowski, and S. J. Nelson, International Society for Magnetic Resonance in Medicine, Sweden, 1/1/2010
• Can Susceptibility-Weighted Imaging Determine Response to Combined Anti-angiogenic, Cytotoxic, and Radiation Therapy in GBM Patients?
  J. M. Lupo , S. Cha, E. Essock-Burns, N. Butowski, and S. J. Nelson, International Society for Magnetic Resonance in Medicine, Sweden, 1/1/2010
• The Effect of Delaying Radiotherapy (RT) In Patients with Newly-diagnosed Glioblastoma Multiforme (GBM) Receiving Temozolomide (TMZ): A Secondary Analysis Based on the...
  N. Butowski, M Polley, K. Lamborn, S. Chang, J Clarke, P Sneed, K. Huang, M. Prados, Society of Neuro-Oncology Annual Meeting, New Orleans, LA, 1/1/2009
• Relationship between Early Perfusion Parameters Derived from DSC MR Imaging and Time-to-Progression in Patients with GBM Following Anti-Angiogenic Therapy
  Emma Essock-Burns, Janine M. Lupo, Soonmee Cha, Susan. M. Chang, Nicholas Butowski, Sarah J. Nelson, American Academy of Neurology Annual Meeting, Chicago, IL, 1/1/2009
• Phase 2 Study of Enzastaurin plus Temozolomide during and following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) Or Gliosarcoma
  N. Butowski, K. Lamborn, S. Chang, D. Thornton, M. Page, Kivett, S. Nicol, M. Prados, American Academy of Neurology Annual Meeting, Chicago, IL, 1/1/2009
• Phase 1/2 Study of Enzastaurin plus Temozolomide during and following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) Or Gliosarcoma
  N. Butowski, K. Lamborn, S. Chang, D. Thornton, R. DeBoer, M. Page, J. Rabbitt, A. Fedoroff, R. Parvataneni, V. Kivett, S. Nicol, M. Prados, American Academy of Neurology Annual Meeting, Chicago, IL, 1/1/2008
• Phase 1/2 and PGx Study of Enzastaurin plus Temozolomide during and following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) Or Glios...
  N. Butowski, K. Lamborn, S. Chang, D. Thornton, R. DeBoer, M. Page, J. Rabbitt, A. Fedoroff, R. Parvataneni, V. Kivett, S. Nicol, M. Prados, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2008
• Join now to see all

Lectures

• DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma. 
  2019 ASCO Annual Meeting - 6/1/2019
• ICBTRT: International Conference on Brain Tumor Research and Therapy 
  1/1/2014
• Overcoming Tumour Hypoxia to Enhance Patient Survival With a Tunable Oxygen-Binding Protein Therapy 
  United Kingdom - 1/1/2014
• Preclinical Evaluation of NT113, a Novel ERBB Inhibitor Optimized for CNS Biodistribution 
  1/1/2013
• Contemporary Management of Glioblastoma 
  1/1/2013
• Reversing Hypoxia In Glioblastoma 
  1/1/2013
• Discussion of Hypoxia and Treatment Resistance in Glioblastoma 
  1/1/2013
• CNS Tumor Board Satellite Educational Series 
  1/1/2013
• Sunrise Session: Epilepsy in Patients with Brain Tumors 
  1/1/2013
• Mid Level Faculty Mentoring Seminar 
  1/1/2013
• Hypoxia In Glioblastoma 
  United Kingdom - 1/1/2012
• I Seve Ballesteros Foundation Translational Neuro-oncology Summit 
  Madrid, Spain - 1/1/2010
• Phase II and Pharmacogenomics (PGx) Study of Enzastaurin (ENZ) plus Temozolomide (TMZ) and Radiation Therapy (RT) in Patients with Glioblastoma Multiforme (GBM) or Gli... 
  New Orleans, LA - 1/1/2009
• Meningioma Update 
  1/1/2009
• Phase I/II and Pharmacogenomics (PGx) Study of Enzastaurin (ENZ) plus Temozolomide (TMZ) and Radiation Therapy (RT) in Patients with Glioblastoma Multiforme (GBM) or G... 
  Barcelona, Spain - 1/1/2008
• Revolution Health Education Talk 
  1/1/2006
• Newly Diagnosed GBM: Proton MR Spectroscopic Characteristics and Correlation with Clinical Outcome 
  Edinburgh, Scotland - 1/1/2005
• Join now to see all